Clinical Trial

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-28.
Trial Details
NCT Number NCT07566988
Lead Sponsor Novartis Pharmaceuticals
Conditions Multiple Sclerosis
Enrollment 2,604 participants
Start Date 2024-10-25
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11